Rocket Lab stock price falls as RKLB slips on Neutron schedule focus ahead of Feb. 26 results

Rocket Lab stock price falls as RKLB slips on Neutron schedule focus ahead of Feb. 26 results

New York, Jan 29, 2026, 14:51 EST — Regular session

  • Rocket Lab shares dropped as the Nasdaq came under pressure in afternoon trading
  • Neutron’s progress remains in focus following the arrival of its “Hungry Hippo” hardware in Virginia
  • Traders are eyeing a late-February earnings update to get fresh timing on Neutron

Rocket Lab Corporation shares slipped 3.1% to $85.84 by 2:38 p.m. EST, after fluctuating between $83 and $89 earlier in the session. The Nasdaq Composite fell roughly 1.4%. Over the past 52 weeks, Rocket Lab’s stock has traded within a $14.71 to $99.58 range. (Investing)

The pullback arrives as investors focus on Neutron, Rocket Lab’s bigger, partly reusable rocket, where even small updates can move the stock. Space.com noted this week that Rocket Lab’s “Hungry Hippo” payload fairing has landed at the Mid-Atlantic Regional Spaceport in Virginia for checkout and pre-launch tests, part of the lead-up to Neutron’s debut flight. (Space)

Timing remains a sticking point. In a January filing, Rocket Lab revealed its Stage 1 tank failed during a hydrostatic pressure test, causing a rupture. The company is now analyzing the data to see how this might affect its launch timeline. It also noted that such test setbacks “are not uncommon” in the qualification phase. (SEC)

Rocket Lab plans to release its fourth-quarter and full-year 2025 earnings after the U.S. market closes on Feb. 26. A conference call will follow at 5:00 p.m. ET. (Rocket Lab Investors)

Options traders are gearing up for more volatility. GuruFocus reports that implied volatility, which gauges anticipated stock fluctuations based on options pricing, climbed to 97.48, signaling a daily price swing close to $5.21. (GuruFocus)

Wall Street isn’t ready to ditch the stock over the pressure-test rupture. A MarketBeat piece on Nasdaq.com noted Bank of America stayed bullish, doubling its price target to $120 from $60. TD Cowen also held firm with a buy rating, hiking its target from $60 to $100. (Nasdaq)

Rocket Lab’s shares, known for their high beta in the space sector, rarely move steadily when the wider market grows wary. Thursday’s decline was no exception.

The downside is straightforward: should Neutron miss the mark again, or if doubts creep into its cost and production timeline, momentum could vanish quickly—especially given the options market’s pricing of large daily swings.

The next catalyst arrives on Feb. 26, as investors expect an updated, tighter Neutron schedule along with fourth-quarter results and guidance.

Stock Market Today

  • Organon & Co. Shares Rise 25% Amid Low P/E Ratio and Earnings Concerns
    January 29, 2026, 3:05 PM EST. Organon & Co. (NYSE:OGN) shares surged 25% in the past month, bouncing back from a 44% decline over the last year. The pharmaceutical firm's low price-to-earnings (P/E) ratio of 4.6x contrasts with the U.S. market average above 20x, signaling skepticism among investors. Despite a challenging year with a 62% decrease in earnings per share and shrinking returns over three years, analysts forecast 20% annual growth over the next three years-above the market's 12% average. The disconnect between Organon's strong earnings outlook and its low P/E suggests investors remain cautious about potential risks. This creates a potential opportunity for value investors to consider Organon shares that may be undervalued.
Newmont stock drops as gold pulls back from record, putting miners’ rally to the test
Previous Story

Newmont stock drops as gold pulls back from record, putting miners’ rally to the test

Go toTop